Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Gynecol Oncol. 2021 Feb 6;160(3):777–785. doi: 10.1016/j.ygyno.2020.12.010

Figure 4: HRD predicts chemo-sensitivity of endometrial cancer cell lines.

Figure 4:

A, HRD scores of endometrial cancer cell lines. B and C, Expression of BRCA1 and 2 in endometrial cancer cell lines. D, Effect of cisplatin treatment on endometrial cancer cell lines. E, Effect of olaparib treatment on endometrial cancer cell lines. F, Effect of paclitaxel treatment on endometrial cancer cell lines. The three cell lines with the highest HRD scores (Hec1a, Hec1b and KLE) were significantly more sensitive to all three agents tested (cisplatin, paclitaxel and olaparib) than were the cell lines with low (Ishikawa) or intermediate HRD score (AN3CA, Hec265)(p<0.001).